Symbols / BBLG Stock $1.20 -3.23% Bone Biologics Corporation
BBLG (Stock) Chart
About
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.15M |
| Enterprise Value | -3.11M | Income | -3.11M | Sales | — |
| Book/sh | 3.00 | Cash/sh | 2.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -0.74 | PEG | — |
| P/S | — | P/B | 0.40 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 12.77 |
| Current Ratio | 13.85 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.65 | EPS next Y | -1.62 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 16:00 | ROA | -41.87% |
| ROE | -70.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.80M |
| Shs Float | 1.79M | Short Float | 1.46% | Short Ratio | 1.10 |
| Short Interest | — | 52W High | 6.75 | 52W Low | 1.05 |
| Beta | 0.37 | Avg Volume | 23.34K | Volume | 13.45K |
| Target Price | $22.20 | Recom | None | Prev Close | $1.24 |
| Price | $1.20 | Change | -3.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.20
Mean price target
2. Current target
$1.20
Latest analyst target
3. DCF / Fair value
$-16.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.20
Low
$22.20
High
$22.20
Mean
$22.20
- Bone Biologics (NASDAQ: BBLG) adds $1.064M at-the-market stock capacity - Stock Titan Fri, 13 Mar 2026 07
- Bone Biologics stock rises after extending product shelf life - Investing.com ue, 23 Dec 2025 08
- If You Invested $1,000 in Bone Biologics Corp (BBLG) - Stock Titan Sun, 22 Mar 2026 13
- Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook - Yahoo Finance hu, 04 Sep 2025 07
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 11
- Bone Biologics Corporation Announces $1 Million At-the-Market Offering of Common Stock Through H.C. Wainwright & Co - Minichart Sat, 14 Mar 2026 07
- Bone-healing treatment in development now lasts 2 years on the shelf in tests - Stock Titan ue, 23 Dec 2025 08
- Bone Biologics (BBLG) Stock Price, News & Analysis - MarketBeat hu, 24 Aug 2023 22
- What is the current Price Target and Forecast for Bone Biologics (BBLG) - Zacks Investment Research Mon, 26 Sep 2022 06
- Bone Biologics Announces Pricing of $5.0 Million Public Offering - Yahoo Finance Fri, 27 Jun 2025 07
- Spine surgery trial moves ahead as Bone Biologics extends bone protein life - Stock Titan hu, 08 Jan 2026 08
- Bone Biologics (BBLG) - Zacks Investment Research Sat, 16 Oct 2021 03
- Why Is OncoSec Medical (ONCS) Stock Down 48% Today? - InvestorPlace hu, 15 Jun 2023 07
- Game-Changing Bone Regeneration Patent: Bone Biologics Advances New Spine Fusion Treatment - Stock Titan Fri, 27 Jun 2025 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace Mon, 10 Jan 2022 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Gross Profit |
|
—
|
—
|
—
|
0.00
|
| Operating Expense |
|
3.23
-23.33%
|
4.22
-55.25%
|
9.43
+157.24%
|
3.67
|
| Research And Development |
|
1.06
-50.23%
|
2.13
-69.16%
|
6.91
+337.40%
|
1.58
|
| Selling General And Administration |
|
2.17
+4.12%
|
2.09
-17.13%
|
2.52
+20.84%
|
2.09
|
| General And Administrative Expense |
|
2.17
+4.12%
|
2.09
-17.13%
|
2.52
+20.84%
|
2.09
|
| Other Gand A |
|
2.17
+4.12%
|
2.09
-17.13%
|
2.52
+20.84%
|
2.09
|
| Total Expenses |
|
3.23
-23.33%
|
4.22
-55.25%
|
9.43
+157.24%
|
3.67
|
| Operating Income |
|
-3.23
+23.33%
|
-4.22
+55.25%
|
-9.43
-157.24%
|
-3.67
|
| Total Operating Income As Reported |
|
-3.23
+23.33%
|
-4.22
+55.25%
|
-9.43
-157.24%
|
-3.67
|
| EBITDA |
|
-3.23
+23.33%
|
-4.22
+55.25%
|
-9.43
-157.24%
|
-3.67
|
| Normalized EBITDA |
|
-3.24
+24.15%
|
-4.27
+56.89%
|
-9.91
-50.61%
|
-6.58
|
| EBIT |
|
-3.23
+23.33%
|
-4.22
+55.25%
|
-9.43
-157.24%
|
-3.67
|
| Total Unusual Items |
|
0.00
-92.23%
|
0.05
-89.31%
|
0.48
-83.60%
|
2.91
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-92.23%
|
0.05
-89.31%
|
0.48
-83.60%
|
2.91
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.41
|
0.00
|
| Other Special Charges |
|
—
|
—
|
0.41
|
—
|
| Net Income |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Pretax Income |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Net Non Operating Interest Income Expense |
|
0.12
+119.16%
|
0.06
+2879.66%
|
0.00
+100.26%
|
-0.73
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
0.12
+119.16%
|
0.06
+2879.66%
|
0.00
+100.26%
|
-0.73
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
0.12
+119.16%
|
0.06
+2879.66%
|
0.00
|
0.00
|
| Interest Income |
|
0.12
+119.16%
|
0.06
+2879.66%
|
0.00
|
0.00
|
| Other Income Expense |
|
0.00
-92.23%
|
0.05
-89.31%
|
0.48
-83.60%
|
2.91
|
| Gain On Sale Of Security |
|
0.00
-92.23%
|
0.05
-94.28%
|
0.89
-69.35%
|
2.91
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Net Income From Continuing And Discontinued Operation |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Net Income Continuous Operations |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Normalized Income |
|
-3.11
+25.23%
|
-4.16
+55.83%
|
-9.43
-114.39%
|
-4.40
|
| Net Income Common Stockholders |
|
-3.11
+57.56%
|
-7.32
+18.15%
|
-8.95
-502.76%
|
-1.48
|
| Otherunder Preferred Stock Dividend |
|
0.00
-100.00%
|
3.21
|
0.00
|
—
|
| Diluted EPS |
|
—
|
-28.96
+85.81%
|
-204.06
-9.18%
|
-186.90
|
| Basic EPS |
|
—
|
-28.96
+85.81%
|
-204.06
-9.18%
|
-186.90
|
| Basic Average Shares |
|
—
|
0.25
+476.80%
|
0.04
+452.13%
|
0.01
|
| Diluted Average Shares |
|
—
|
0.25
+476.80%
|
0.04
+452.13%
|
0.01
|
| Diluted NI Availto Com Stockholders |
|
-3.11
+57.56%
|
-7.32
+18.15%
|
-8.95
-502.76%
|
-1.48
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
0.73
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
3.74
|
| Current Assets |
|
3.74
|
| Cash Cash Equivalents And Short Term Investments |
|
3.03
|
| Cash And Cash Equivalents |
|
3.03
|
| Cash Financial |
|
3.03
|
| Receivables |
|
0.33
|
| Other Receivables |
|
0.33
|
| Accrued Interest Receivable |
|
—
|
| Prepaid Assets |
|
0.71
|
| Total Non Current Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
0.83
|
| Current Liabilities |
|
0.83
|
| Payables And Accrued Expenses |
|
0.78
|
| Payables |
|
0.36
|
| Accounts Payable |
|
0.36
|
| Current Accrued Expenses |
|
0.41
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Other Current Liabilities |
|
0.06
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Stockholders Equity |
|
2.91
|
| Common Stock Equity |
|
2.91
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.09
|
| Ordinary Shares Number |
|
0.09
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
83.81
|
| Retained Earnings |
|
-80.91
|
| Total Equity Gross Minority Interest |
|
2.91
|
| Total Capitalization |
|
2.91
|
| Working Capital |
|
2.91
|
| Invested Capital |
|
2.91
|
| Net Tangible Assets |
|
2.91
|
| Tangible Book Value |
|
2.91
|
| Current Notes Payable |
|
—
|
| Interest Payable |
|
—
|
| Line Of Credit |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.69
+34.76%
|
-4.12
+56.83%
|
-9.56
-167.90%
|
-3.57
|
| Cash Flow From Continuing Operating Activities |
|
-2.69
+34.76%
|
-4.12
+56.83%
|
-9.56
-167.90%
|
-3.57
|
| Net Income From Continuing Operations |
|
-3.11
+24.40%
|
-4.11
+54.04%
|
-8.95
-502.76%
|
-1.48
|
| Other Non Cash Items |
|
—
|
—
|
—
|
0.73
|
| Stock Based Compensation |
|
0.26
+35.77%
|
0.19
+23.74%
|
0.15
-42.77%
|
0.27
|
| Operating Gains Losses |
|
-0.00
+92.23%
|
-0.05
+94.28%
|
-0.89
+69.35%
|
-2.91
|
| Gain Loss On Investment Securities |
|
-0.00
+92.23%
|
-0.05
+94.28%
|
-0.89
+69.35%
|
-2.91
|
| Change In Working Capital |
|
0.17
+210.11%
|
-0.15
-213.04%
|
0.13
+178.94%
|
-0.17
|
| Change In Receivables |
|
-0.01
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
0.08
-51.81%
|
0.17
-28.80%
|
0.25
+125.68%
|
-0.96
|
| Change In Payables And Accrued Expense |
|
0.09
+127.99%
|
-0.33
-148.48%
|
0.67
+13655.69%
|
0.00
|
| Change In Accrued Expense |
|
0.00
+100.00%
|
-0.41
-200.00%
|
0.41
|
0.00
|
| Change In Payable |
|
0.09
+1.39%
|
0.09
-64.91%
|
0.26
+5146.59%
|
0.00
|
| Change In Account Payable |
|
0.09
+1.39%
|
0.09
-64.91%
|
0.26
+5146.59%
|
0.00
|
| Change In Other Working Capital |
|
—
|
—
|
-0.78
-200.00%
|
0.78
|
| Financing Cash Flow |
|
4.70
+6.26%
|
4.42
-12.30%
|
5.04
+13.87%
|
4.43
|
| Cash Flow From Continuing Financing Activities |
|
4.70
+6.26%
|
4.42
-12.30%
|
5.04
+13.87%
|
4.43
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
4.70
+79.66%
|
2.62
-48.13%
|
5.04
+13.87%
|
4.43
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
1.81
|
0.00
|
—
|
| Changes In Cash |
|
2.01
+572.96%
|
0.30
+106.62%
|
-4.51
-622.83%
|
0.86
|
| Beginning Cash Position |
|
3.33
+9.86%
|
3.03
-59.85%
|
7.54
+12.93%
|
6.68
|
| End Cash Position |
|
5.33
+60.42%
|
3.33
+9.86%
|
3.03
-59.85%
|
7.54
|
| Free Cash Flow |
|
-2.69
+34.76%
|
-4.12
+56.83%
|
-9.56
-167.90%
|
-3.57
|
| Interest Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
4.70
+79.66%
|
2.62
-48.13%
|
5.04
+13.87%
|
4.43
|
| Issuance Of Capital Stock |
|
4.70
+79.66%
|
2.62
-48.13%
|
5.04
+13.87%
|
4.43
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-13 View
- 10-K2026-03-02 View
- 42026-01-21 View
- 42026-01-21 View
- 8-K2026-01-08 View
- 10-Q2025-11-14 View
- 8-K2025-09-04 View
- 10-Q2025-08-14 View
- 8-K2025-06-30 View
- 8-K2025-06-26 View
- 42025-06-06 View
- 42025-06-06 View
- 42025-06-06 View
- 42025-06-06 View
- 8-K2025-06-06 View
- 8-K2025-05-30 View
- 10-Q2025-05-12 View
- 8-K2025-04-11 View
- 8-K2025-04-01 View
- 10-K2025-02-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|